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Background: Macrophages are abundantly present in the airways. After allergen 
contact, macrophages can respond with different states of polarization at the cost of 
their anti-inflammatory polarization state. The different macrophage functional states 
have not been investigated in lung tissue of asthmatics and healthy controls and it is 
unknown how they relate to disease severity and treatment response.
Objective: We quantified different polarization states of macrophages in asthma 
patients and healthy controls and studied associations with lung function, sex and 
inhaled corticosteroid (ICS) use.
Methods: Bronchial biopsies from 138 well-characterized asthma patients and 50 
matched healthy controls were stained for different macrophage subsets defined by 
a general macrophage marker (CD68) in combination with subset-specific markers, 
namely interferon regulatory factor 5 (IRF5), CD206, and IL-10 respectively. Double-
positive cells were counted and expressed as the number of cells per mm basement 
membrane.
Results: Asthma patients had higher numbers of IRF5+ and CD206+ macrophages in 
bronchial biopsies than healthy individuals, males having more IRF5+ and females 
more CD206+ macrophages. Asthma patients had lower numbers of IL-10+ macro-
phages than healthy individuals, while ICS users had more than non-ICS users. Higher 
numbers of IRF5+ macrophages were associated with more severe airflow obstruction 
(lower FEV1/FVC) and higher numbers of IL-10+ macrophages with less severe airflow 
obstruction.
Conclusions: This study suggests that macrophages are differentially polarized in asth-
ma. Their polarization state can be linked to disease severity, sex and ICS treatment. 
Specifically increasing the number of IL-10+ macrophages by therapeutic intervention 
may be a novel way of treating asthma.
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Introduction
A number of recent reports have shown that macrophages in the lungs are important 
in maintaining homeostasis, yet they can significantly contribute to the development 
of asthma (1–7). This contradiction in functions can be explained by their plasticity. In 
vitro studies have delineated three main polarization states of macrophages, which 
is a simplified model of the in vivo situation (8, 9). These polarization states contain 
two types associated with inflammatory responses, and one with anti-inflammatory 
responses.
The macrophage subset associated with Th1 inflammation is induced by interferon 
gamma (IFNγ), tumor necrosis factor alpha (TNFα) and/or microbial products, and 
is characterized by interferon regulatory factor 5 (IRF5) expression and production 
of pro-inflammatory cytokines (10, 11). The second macrophage subset, associated 
with Th2 inflammation, is induced by interleukin (IL)-4 and/or IL-13. It is characterized 
by increased expression of uptake receptors, including CD206 (mannose receptor) 
and is important in tissue repair processes (12, 13). The third macrophage subset, 
associated with downregulation of inflammation, is induced by corticosteroids and 
IL-10. It shares many markers with IL-4/IL-13-induced macrophages, such as CD206, 
but additionally produces high levels of anti-inflammatory IL-10 (8).
As CD206+ macrophages are induced by the archetypical asthma cytokines IL-4/IL-13, 
their numbers and function have been studied more extensively in asthma than IRF5+ 
and IL-10+ macrophages. We and others found higher numbers of CD206+ macro-
phages or their products in the lungs of asthmatics compared to healthy controls, 
though in relatively small sample size cohorts (14–17). Moreover, we showed that 
higher CD206+ macrophage numbers are associated with more severe asthma (14) 
and that these IL-4/IL-13-induced macrophages contribute to asthma development in 
mouse models of allergic lung inflammation (2, 18, 19).
To the best of our knowledge, no publications have reported the numerical pres-
ence of Th1-associated IRF5+ or anti-inflammatory IL-10+ macrophages in human 
asthma. However, there is data showing higher levels of inducing factors for IRF5+ 
macrophages and their products in asthma than in healthy controls (20, 21). Addi-
tionally, inducers and products of these macrophages have been found associated 
with corticosteroid-resistant, severe asthma (22–24). In murine models of asthma we 
found more IRF5+ macrophages and less IL-10+ macrophages in lungs of mice with 
allergic lung inflammation than in controls (3, 25).
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In this study we set out to narrow the knowledge gap on the presence of different 
macrophage polarization states in human asthma by comparing individuals with and 
without asthma. Based on the few reports present, mostly from animal models, we 
hypothesized that human asthma is characterized by higher numbers of IRF5+ and 
CD206+ macrophages and lower numbers of anti-inflammatory IL-10+ macrophages. 
In addition, we investigated whether these three polarization states correlate with 
disease severity and/or treatment response in asthma. To this aim, we quantified 
the three main polarization states of macrophages in airway wall biopsies in a large 




Bronchial wall biopsies of asthma patients (n=138) and healthy individuals (n=50) 
originated from cohorts previously studied by our group (26, 27). The experimental 
protocols were approved by the Medical Ethical Committee of the UMCG (METc 
2007/007, clinicaltrials.gov NCT00848406) and all subjects gave written informed 
consent. Table I presents the clinical characteristics of all subjects. All lung function 
parameters were significantly lower in asthma patients than in healthy individuals. 
Most patients showed mild to moderate asthma symptoms. Male patients had a 
significantly lower lung function as assessed by forced expiratory volume in 1 second 
(FEV1) (%predicted) and maximal expiratory flow (MEF50) (%predicted) than female 
patients.
Asthma patients
Asthma patients had a doctor’s diagnosis of asthma and documented reversibility and 
bronchial hyperresponsiveness (BHR) to histamine in the past. Asthma patients were 
extensively re-examined (see for study design reference (26, 28) and were included 
in the study if they showed a positive AMP provocation test (PC20AMP < 320 mg/mL), 
or if this was >320 mg/mL a positive histamine provocation test (PC20histamine < 32 
mg/mL).
Healthy individuals
Healthy individuals were included if they met the following criteria: 1) normal pul-
monary health according to the physician, 2) normal spirometry defined as FEV1 ≥ 80 
%predicted, an FEV1/forced vital capacity (FVC) greater than the lower limit of normal, 
3) no bronchodilator reversibility defined as an increase in FEV1 < 10% of the predicted 
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value after administration of 400 μg salbutamol, and 4) no bronchial hyperresponsive-
ness to methacholine. Never-smokers were defined as subjects who had not smoked 
during the last year, had never smoked for as long as 1 year, and had not smoked more 
than 0.5 packyears.
Lung function
A daily-calibrated spirometer was used to perform lung function tests according to 
standardized guidelines as previously described (29). FEV1 was measured with a cali-
brated water-sealed spirometer (Lode Spirograph D53, Lode Instruments, Groningen, 
The Netherlands) according to standardized guidelines (29, 30). After administration 
of 400 μg albuterol the reversibility of FEV1 (% predicted) was measured. Provocation 
Table I. Patient characteristics. Most patients showed mild to moderate asthma symptoms. Values are medi-






Sex, males/females 70/68 29/21 n.s.
Age, years 49 (17-71) 51 (19-73) n.s.
Body mass index, kg/m2 26.7 (19-44.2) 23.4 (19-35.8) n.s.
Atopy, n (%) (positive skin prick test) 95 (69) 18 (37) p<0.0001
Current smoking, n (%) 30 (22) 17 (34) n.s.
ICS use, yes/no 57/81 0/50 p<0.0001
β2 agonist use, yes/no 71/67 n.d. -
IgE 78 (1-1668) n.d. -
PC20AMP, mg/mL 198 (0-640) 640 (66.7-640) p<0.0001
FEV1, % predicted 93 (34-134) 111 (88-139) p<0.0001
FEV1/VC, % 72 (40-96) 78 (68-93) p<0.0001
MEF50, % predicted 73 (17-152) 88 (57-136) p<0.01





Blood neutrophils, x109/L 3.3 (1.4-66.7) 2.8 (1.3-7.6) p<0.01
Lung eosinophils, numbers per 0.1 mm2 tissue area 1.8 (0-40) n.d. -
Lung neutrophils, numbers per 0.1 mm2 tissue area 6.2 (0-46) n.d. -
Lung CD3+ T cells, numbers per 0.1 mm2 tissue area 67.6 (4.2-294) n.d. -
NO alveolar, ppb 5.3 (2.6-51.7) 3.7 (-0.28-67.8) p<0.001
NO bronchial, nl/s 0.7 (0.08-10.4) 0.6 (-2.67-3.6) n.s.
Basement membrane thickness, μm 5.9 (2.8-12.6) 3.1 (1.6-7.0) p<0.0001
Goblet cells, number per 1 mm basement membrane 36 (0-220) n.d. -
Collagen III deposition area, % 28 (3-66) n.d. -
Definition of abbreviations: ICS = inhaled corticosteroid; PC20AMP = provocative concentrations of adenosine 
5’monophosphate causing a 20% fall in FEV1 ; MEF50 = maximum expiratory flow rate at 50% of vital capacity; 
n.s.= not significant; n.a.= not applicable; n.d.= no data.
Chapter 5
108
tests were performed as published previously (28, 31). Subjects received an initial 
nebulized 0.9% saline challenge, followed by doubling concentrations of AMP (0.04-
320 mg/mL) by 2-minute tidal breathing at intervals of 5 minutes. BHR to histamine 
was measured by doubling concentrations ranging from 0.13 to 32 mg/mL using the 
30-second tidal breathing method (32).
Collection and processing of bronchial biopsies
Bronchial biopsies were collected with a flexible bronchoscope (type Olympus BF P20 
or BF XT20; Olympus, Center Valley, PA) under local anesthesia. The biopsies were 
obtained from segmental divisions of the main bronchi and thereafter fixed in 4% 
formalin. After processing, the biopsies were embedded in paraffin and cut into sec-
tions of 3 μm thickness.
Histology
To identify macrophage subsets in bronchial biopsies, a general macrophage marker 
CD68 was used in combination with subset-specific markers. Our previous studies 
in lungs and livers showed that IRF5 is a selective marker for the presence of pro-
inflammatory macrophages when combined with the general macrophage marker 
CD68 (3, 25, 33).
Numbers of pro-inflammatory IRF5+ macrophages were determined by double stain-
ing of CD68 (anti-CD68, DAKO, Heverlee, Belgium) and IRF5 (anti-IRF5, ProteinTech 
Europe, Manchester, UK), pro-inflammatory CD206+ macrophages by double staining 
of CD68 (anti-CD68, Abnova, Heidelberg, Germany) and CD206 (anti-CD206, Serotec, 
Puchheim, Germany), and anti-inflammatory macrophages by double staining of 
CD68 (anti-CD68, DAKO) and IL-10 (anti-IL10, Hycult Biotech, Uden, The Netherlands) 
using standard immunohistochemical procedures. In short, sections were deparaf-
finized and antigen retrieval was performed by overnight incubation in Tris-HCL buffer 
pH 9.0 at 80°C; thereafter sections were incubated with rabbit anti-IRF5 followed by 
mouse anti-CD68 or mouse anti-CD206 followed by rabbit anti-CD68. Next, sections 
were incubated with the two secondary antibodies together: horseradish peroxidase 
(HRP)-conjugated goat-anti-mouse antibody and alkaline phosphatase (AP)-conjugat-
ed goat-anti-rabbit antibody.
For IL-10 stainings, antigen retrieval was performed by heating the sections in citrate 
buffer at pH 6.0 for 10 minutes at sub-boiling temperature. The sections were pre-
treated with 1% bovine serum albumin (Sigma Aldrich, Zwijndrecht, The Netherlands) 
and 5% milk powder in PBS for 30 minutes and incubated with rabbit anti-IL-10 over-
night. Next day, the sections were incubated with mouse anti-CD68 followed by the 
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two secondary antibodies together: HRP-conjugated goat-anti-rabbit antibody and 
alkaline AP-conjugated goat-anti-mouse antibody.
First the AP-conjugated antibodies were visualized using an immunoalkaline phospha-
tase procedure with 5-bromo-4-chloro-3-indolyl-phosphate/ nitro blue tetrazolium 
(BCIP/NBT) as chromogen (Vector, Burlingame, CA, USA). Next, the HRP-conjugated 
antibodies were visualized with ImmPACT NovaRED (Vector, Burlingame, CA, USA) as 
chromogen.
All stainings were quantified by morphometric analysis using ImageScope analysis 
software (Aperio, Vista, CA, USA). A blinded observer manually counted the double-
positive cells in whole bronchial biopsy sections per length of intact basement 
membrane and extending 100 μm into the intact submucosa, excluding vessel and 
smooth muscle. Data was expressed as the number of positive cells per millimeter of 
basement membrane.
Statistics
Normality of distributions was assessed using D’Agostino-Pearson omnibus test. When 
data was not normally distributed log or square root transformations were performed. 
Student’s t tests were used to compare macrophage subsets between two groups. 
Data is shown as aligned dot plots with line at median. Pearson correlations were 
performed on macrophage subsets and clinical characteristics. Multiple regression 
analyses were performed within the asthma population to explain the contribution 
of each macrophage subset (independent variable of model 1: IRF5+ macrophages, 
model 2: IL-10+ macrophages and model 3: CD206+ macrophages) to the variation of 
lung function (dependent variable). This regression analysis was performed to explain 
bronchial hyperresponsiveness (PC20AMP mg/mL), airway obstruction (FEV1, L and 
%predicted, and FEV1/FVC ratio), small airway obstruction (MEF25, MEF50, and MEF75, 
(L/s)), and use of inhaled corticosteroids (ICS) (yes/no). All models were adjusted for 
sex, age, height, and current smoking. P-values <0.05 were considered significant. 
Data were analyzed using Graphpad Prism 6 and IBM SPSS Statistics version 22.
Results
Macrophage subsets in asthma patients versus healthy individuals
Total numbers of macrophages (CD68+) were not significantly different between 
healthy individuals and asthma patients (Figure 1A). Higher numbers of IRF5+ mac-
rophages and CD206+ macrophages were found in bronchial biopsies of asthma 
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patients as compared to healthy individuals (P<0.0001; Figures 1B and C). Lower num-
bers of IL-10+ macrophages were present in bronchial biopsies of asthma patients as 
compared to healthy individuals (P<0.0001; Figure 1D). Representative photos of the 
double stainings are shown in figures 1E-G. No obvious differences in the location of 
macrophage subsets were observed.
Macrophages and clinical characteristics of asthma patients
Table II presents results of monovariate regression analysis of the macrophage sub-
sets with clinical characteristics of the asthmatics. No differences were found in the 
total numbers of macrophages between sexes in both healthy individuals and asthma 
patients (Figure 2A). Both males and females with asthma had higher numbers of 
IRF5+ and CD206+ macrophages in bronchial biopsies as compared to healthy males 
and females, respectively (both P<0.001). Within asthma patients, males had higher 
numbers of IRF5+ macrophages than females (P<0.001; Figure 2B), whereas females 
had higher numbers of CD206+ macrophages (P<0.001; Figure 2C). Numbers of IL-
10+ macrophages were not significantly different between sexes, but both asthmatic 
males and females had lower numbers of IL-10+ macrophages as compared to healthy 


















































































































































Figure 1. Aligned dot plots with line 
shown at median of macrophages in 
bronchial biopsies of asthma patients 
versus healthy individuals. Number of 
(A) all CD68+ cells, (B) IRF5+CD68+, (C) 
CD206+CD68+, and (D) IL-10+CD68+ 
cells in healthy subjects and asthma 
patients. Representative photos of (E) 
IRF5+CD68+, (F) CD206+CD68+, and (G) 
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Since male asthmatics had a significantly lower lung function as assessed by FEV1 
(%predicted) and MEF50 (%predicted) than female asthmatics, the above reported sex 
differences in IRF5+ and CD206+ macrophages may be influenced by the difference 
in lung function. Therefore, male and female asthmatics were arbitrary divided in 
those with worse lung function (FEV1 <85% predicted) and with better lung function 
(FEV1 > 85% predicted). Asthmatic males FEV1< 85% predicted had higher numbers of 
IRF5+ macrophages than asthmatic females with FEV1 less than 85% predicted (P<0.5; 
Figure 2E), whereas females had higher numbers of CD206+ macrophages than males 
(P<0.05; Figure 2G). Similar results were shown in bronchial biopsies of asthmatic 
males and females with FEV1 more than 85% predicted: more IRF5+ macrophages in 
males than in females (P<0.001; Figure 2F) and more CD206+ macrophages in females 
than in males (P<0.01; Figure 2H).
Asthma patients using ICS had similar numbers of total macrophages in bronchial 
biopsies as non-ICS-using asthmatics (Figure 3A), but lower numbers of IRF5+ mac-
rophages and higher numbers of IL-10+ macrophages (Figures 3B and D), without 
differences in CD206+ macrophage numbers (Figures 3C). There were no significant 
differences observed between males and females using ICS as compared to males 
and females who did not use ICS, respectively (Figure E-G). IL-10+ macrophages were 
higher in both males and females using ICS as compared to males and females not 
using ICS, respectively (both P<0.01, Figure 3H).
Higher numbers of IRF5+ macrophages were significantly associated with a lower 
FEV1/FVC ratio (Figure 4A), and higher IL-10+ macrophage numbers with higher FEV1/
Table II. Pearson correlations of macrophages subset (IRF5+CD68+, CD206+CD68+ or IL-10+CD68+) and clini-
cal charcteristics. Categorical variables (Sex, ICS and smoking) tested with t-test.
IRF5+CD68+ CD206+CD68+ IL-10+CD68+
r p-value r p-value r p-value
Sex (male/female) Figure 2B 0.000 Figure 2C 0.001 Figure 2D 0.083
Age (years) 0.124 0.148 -0.045 0.598 -0.057 0.503
ICS use (no/yes) Figure 3B 0.028 Figure 3C 0.489 Figure 3D 0.011
Current smoking (no/yes) - 0.828 - 0.846 - 0.361
PC20 AMP (mg/mL) 0.048 0.577 -0.130 0.139 -0.123 0.166
FEV1 (%predicted) -0.147 0.088 -0.020 0.825 -0.028 0.758
FEV1/FVC (%) -0.204 0.017
Figure 4A
0.132 0.134 0.183 0.038
Figure 4B
MEF50 L/s -0.029 0.735 0.039 0.648 -0.001 0.994
IRF5+CD68+ - - - - - -
CD206+CD68+ 0.055 0.535 - - - -
IL-10+CD68+ -0.007 0.940 0.041 0.652 - -
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Figure 2. Aligned dot plots with line shown at median of macrophages in bronchial biopsies of male and fe-
male asthma patients. Number of (A) all CD68+ cells, (B) IRF5+CD68+, (C) CD206+CD68+, and (D) IL-10+CD68+ 
cells in all male and female asthma patients. Number of IRF5+CD68+ cells and CD206+CD68+ cells in male and 
female asthma patients with a lower FEV1 (%predicted) than 85 (E and F) and with a higher FEV1 (%predicted) 
than 85 (G and H). ***P<0.001.
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Figure 3. Aligned dot plots with line shown at median of macrophage in bronchial biopsies of non-users and 
users of ICS. Number of (A) all CD68+ cells, (B) IRF5+CD68+, (C) CD206+CD68+, and (D) IL-10+CD68+ cells in 
healthy subjects and asthma patients. Number of (E) all CD68+ cells, (F) IRF5+CD68+, (G) CD206+CD68+, and 
(H) IL-10+CD68+ cells in both male and female asthma patients using ICS and not using ICS. *P<0.05.
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FVC ratio values (Figure 4B). No significant associations were found with other lung 
function parameters (see table I for for all lung function parameters). CD206+ macro-
phages were not associated with lung function at all. None of the macrophage subsets 
was associated with age, current smoking (no/yes), eosinophils, neutrophils or airway 
remodelling, as reflected by basement membrane thickness, goblet cell numbers 
and collagen III deposition (data not shown). There were no significant associations 
between the presences of the different macrophage subsets themselves.
Macrophage polarization is associated with ICS use, but not with lung function 
parameters
Multiple regression analysis showed that lower numbers of IRF5+ macrophages and 
higher numbers of IL-10+ macrophages were significantly associated with ICS use, 
independent of sex, age and height (Table III). CD206+ macrophages were not sig-
nificantly associated with ICS use. No significant associations were present between 
macrophage subsets and lung function parameters, including PC20AMP (mg/mL), FEV1 
(L), FEV1/FVC ratio, MEF25, MEF50 and MEF75, (L/s) in this model.
















Pearson r = 0.183
















Pearson r = -0.204
Figure 4. Linear regression of (A) IRF5+CD68+ cells and FEV1/FVC ratio, and (B) IL-10+CD68+ cells and FEV1/FVC 
ratio in asthma patients. Both *P<0.05.
Table III. Multiple regression analysis showed that lower numbers of IRF5+ macrophages (model 1) and higher 
numbers of IL-10+ macrophages (model 2) were significantly associated with ICS use (no/yes), independently 
of sex, age and height. No associations were found for CD206+ macrophages (model 3).
Model 1 Model 2 Model 3
R2=0.032 R2=0.414 No associations
B S.E. p-value B S.E. p-value —-
IRF5+ macrophages -0.363 0.173 0.037 —- —- —- —-
IL-10+ macrophages —- —- —- 0.249 0.049 0.000 —-
B= regression coefficient; S.E= standard error.
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Discussion
This is the first study to investigate different macrophage polarization states in a large 
population of asthma patients and healthy subjects. Our results show that both male 
and female asthma patients have similar numbers of total macrophages in bronchial 
biopsies as compared to healthy individuals, but higher numbers of inflammation- 
and remodelling-associated IRF5+ and CD206+ macrophages and lower numbers 
of IL-10+ macrophages. Within the group of asthmatics, male subjects had more 
IRF5+ macrophages than female subjects, whereas this was the other way around 
for CD206+ macrophages. Finally, corticosteroid treatment was associated with more 
IL-10+ macrophages irrespective of sex.
An interesting finding of our study is that we observed higher numbers of IRF5+ 
macrophages in asthmatics than healthy controls. Although asthma is dominated by 
the presence of IL-4 and IL-13 cytokines that induce CD206+ macrophages, previous, 
indirect, evidence suggested that IRF5+ macrophages may also be induced in asthma 
(20, 21, 34). We have now provided direct evidence that IRF5+ macrophages are 
indeed also present in asthma. Murine studies suggest that IRF5+ macrophages can 
aggravate established asthma (35), and this is supported by our results since higher 
numbers of IRF5+ macrophages in airway wall biopsies associate with lower FEV1/
FVC values. Some reports have suggested that IRF5+ macrophages contribute to 
corticosteroid-resistant severe asthma (22–24) and that IRF5+ macrophages them-
selves may be steroid-resistant (36–38). However, we found lower numbers of IRF5+ 
macrophages in asthmatics who used ICS than in non-users, suggesting that these 
macrophages may be able to respond to treatment. We have to keep in mind that this 
is a cross-sectional study, and there may be additional changes in IRF5+ macrophages 
or other mechanisms that render severe asthmatics corticosteroid insensitive. As our 
patients had mostly mild to moderate asthma, this did not allow us to investigate 
severe asthma in more detail.
We found that male asthmatics had more IRF5+ macrophages than female asthmat-
ics. As IRF5+ macrophages associate with worse lung function in our study, this could 
explain the significant differences in lung function between males and females in our 
asthma population. However, when we compared males and females with similar low 
lung function, males still had more IRF5+ macrophages than females. Therefore this 
characteristic appears to be linked to male sex and not to the differences in lung 
function. Similarly, female sex was linked to having more CD206+ macrophages as 
compared to male sex, irrespective of lung function. We have previously shown simi-
lar differences in murine models of asthma (2, 25). The reason for these differences 
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between male and female asthmatics are unknown, but may be related to the dif-
ferent levels of sex hormones males and females are exposed to. Interestingly, sexu-
ally disparate polarization of macrophages with more M1 in males and more M2 in 
females has also been shown in a model of myocarditis (39). In this study macrophage 
polarization was influenced by sex hormone-driven IFNγ or IL-4 production by NK 
cells: testosterone was found to favor IFNγ-production by NK cells, whereas estrogen 
favored IL-4 production. As NK cells also play a role in asthma pathogenesis (40), this 
hypothesis warrants further investigation.
As expected, we found higher numbers of Th2-associated CD206+ macrophages in 
bronchial biopsies of asthmatics than in healthy subjects. Since high levels of the 
inducers (IL-4 and IL-13) of CD206+ macrophages are usually present in asthma, 
these macrophages have been more extensively studied in asthma and similar higher 
CD206+ macrophage numbers have been reported by us and others (14–17). These 
macrophages also appeared not be susceptible to corticosteroid treatment. However, 
IL-10+ anti-inflammatory macrophages also express CD206 and after subtraction of 
the IL-10+ subset, we also found lower numbers of CD206+ macrophages in ICS-users 
suggesting that this polarization state may also be susceptible to corticosteroid inhibi-
tion (data not shown).
The function of CD206+ macrophages is in particular linked to remodelling processes. 
Airway remodeling, as defined as increased basement membrane thickness, increased 
collagen III deposition and goblet cell hyperplasia, is known to be an important aspect 
of asthma (42, 43). Our asthmatics indeed showed increased basement membrane 
thickness as compared to controls (26, 28). However, we found no statistical evidence 
that CD206+ contributed to remodeling processes in these patients because their 
number did not correlate with basement membrane thickness, goblet cell numbers 
or collagen III deposition. Since both CD206+ and IRF5+ macrophages are present in 
higher numbers in asthma, we also checked if the ratio of CD206+ to IRF5+ macro-
phages was in any way correlated to remodeling parameters. Again, no significant cor-
relations were found (data not shown). The cross-sectional nature of our study may 
have obscured correlations between CD206+ macrophages and remodeling processes 
and therefore a longitudinal set up may be needed to give a more definitive answer.
As we hypothesized, the numbers of IL-10+ macrophages were lower in asthmatics 
compared to healthy controls. This explains previous in vitro findings that macro-
phages from lavage fluid of asthmatics produce less IL-10 than macrophages from 
healthy subjects (44–46). In contrast, there are also studies that report higher levels 
of IL-10 in asthmatics as compared to healthy subjects. An explanation for these differ-
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ent findings could be the use of ICS by the majority of the asthmatics in these studies, 
which may have influenced IL-10 production by alveolar macrophages. Studies by Ma-
neechotesuwan et al. and John et al. have shown that corticosteroid use can increase 
IL-10 production by lung macrophages (45, 47). This is in line with our results showing 
that ICS treatment was accompanied by higher numbers of IL-10+ macrophages. In 
addition, we found that a higher number of IL-10+ macrophages was associated with 
a higher FEV1/FVC ratio. This is of interest because these macrophages may therefore 
be beneficial in reducing asthma symptoms. Strategies to boost numbers of IL-10+ 
macrophages may be a good avenue to explore for novel asthma treatments. For a 
number of asthmatics this can be done through ICS treatment, but for those patients 
not responding to ICS novel macrophage-polarizing therapies may be an interesting 
option, as these patients are generally difficult to treat.
A limitation of our study is the cross-sectional nature, but the size of our population 
is an asset and the largest study on macrophage polarization states in asthma to date. 
Longitudinal studies have to further elucidate a cause-effect mechanism between 
changes in macrophage polarization and the severity of asthma and its treatment with 
ICS. Furthermore, there are some limitations to subdividing macrophages into three 
polarization states while in vivo they appear as a continuous spectrum rather than 
discrete subsets (8). The total number of CD68+ macrophages is lower than the sum 
of the three polarizations states, indicating that there is indeed overlap in markers.
The strength of the current study is the combination of general macrophage marker in 
combination with subset-specific markers. Generally three main ends of polarization 
are recognized and we used distinct markers for each polarization end state (9). The 
identification of CD206+ macrophages is still complicated, since these macrophages 
share many characteristics with anti-inflammatory IL-10+ macrophages. Most of the 
current studies only distinguish Th1-associated macrophages from Th2-associated 
macrophages by identifying the latter with the broadly accepted mannose receptor 
(CD206) (17, 49). However, CD206 is also expressed by IL-10+ macrophages (50). 
Currently, there is no marker available that reliably identifies human genuine Th2-
associated CD206+ macrophages without the help of IL-10 costaining, the most reli-
able characteristic of anti-inflammatory macrophages to date (8). This has to be kept 
in mind when observing data of CD206+ macrophages, including ours. Our data show 
that IL-10+ macrophage numbers are low, especially in asthma, and when subtracted 
from the CD206+ subset, the genuine Th2-associated CD206+ subset is still higher in 
asthmatics than in controls (data not shown).
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In conclusion, we show in a large population of asthma patients and healthy controls 
that numbers of IRF5+ and CD206+ macrophages are higher in bronchial biopsies of 
asthma patients, whereas IL-10+ macrophage numbers are lower than in healthy con-
trols. We show that IRF5+ macrophages are linked to worse lung function and male 
sex, while female asthma is associated with more CD206+ macrophages. Both sexes 
have less IL-10+ macrophages than healthy controls, and ICS treatment is associated 
with having more IL-10+ macrophages. Our data provide supportive evidence that an 
increase in the number of IL-10+ macrophages by a therapeutic intervention may be 
a novel avenue to explore for the treatment of asthma.
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